Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 273

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 273
---
 and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES |

| 1. | Between September 2004 and December 2015, the Company received funding from the IIA for its participation                                 
 in certain research and development activities, based on budgets approved by the IIA, subject to the fulfillment of specified milestones. 
 The Company is committed to pay royalties to the IIA on proceeds from sale of products related to research and development activities     
 of which the IIA participates by way of grants. According to the funding terms, royalties between 3% and 4.5% are payable on sales        
 of developed products funded, up to 100% of the grant received by the Company, linked to U.S. dollar and bearing Term SOFR interest       
 rate. In the case of failure of a funded research and development activity, the Company is not obligated to pay any such royalties        
 to the IIA. As of December 31, 2024, total contingent obligation to IIA is at the amount of $2,665 (including interest at the amount      
 of $321).                                                                                                                                 |

| 2. | In February 2018, the Company entered into a services agreement with Baxter Healthcare Corporation                                     
 (the “Baxter Services Agreement” and “Baxter”, respectively), pursuant to which the Company agreed to purchase                         
 certain services from Teva Medical (Marketing) Ltd. (“Teva”) in connection with GelrinC. In April 2022, we amended the                 
 Baxter Services Agreement to replace Teva as the supplier of Tisseel under the Supply Agreement for GelrinC with Baxter as Teva ceased 
 to distribute Tisseel in Israel.                                                                                                       |

Under the Baxter Services Agreement,
Baxter provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for
all such support. In consideration for receiving such support, the Company pays Baxter $60 per year until the Company received Food and
Drug Administration (the “FDA”) approval to market GelrinC in the United States. Following FDA approval to market GelrinC
in the United States, the Company will pay Baxter $200 per year during the term of this Services Agreement; however, the year the Company
will receive an FDA approval to market GelrinC in the United States, the Company must pay the remining $140 balance for that year within
30 days after receiving such approval. The Company incurred expenses under the Services Agreement of $